Share This Page
Drug Price Trends for NDC 00998-0630
✉ Email this page to a colleague
Average Pharmacy Cost for 00998-0630
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00998-0630
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MAXITROL 0.1% SUSP,OPH | Harrow Eye, LLC | 00998-0630-06 | 5ML | 64.08 | 12.81600 | 2024-03-15 - 2029-03-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexium (Esomeprazole Magnesium) Market Analysis and Price Projections
What is the Current Market Landscape for Nexium (Esomeprazole Magnesium)?
Nexium, the brand-name formulation of esomeprazole magnesium, is a proton pump inhibitor (PPI) used to treat conditions associated with excessive stomach acid production. Its primary indications include gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and as part of a regimen to eradicate Helicobacter pylori. The active pharmaceutical ingredient (API) is esomeprazole, which is the S-isomer of omeprazole.
The market for Nexium has been significantly impacted by patent expiries and the subsequent introduction of generic versions. Nexium's primary U.S. patent expired in 2014, opening the door for generic competition. This has led to a substantial decline in the brand-name drug's market share and pricing power.
Key Market Participants:
- Brand-Name Manufacturer: AstraZeneca PLC (historically, now less dominant in the branded market due to generics).
- Generic Manufacturers: Numerous pharmaceutical companies have launched generic esomeprazole magnesium products. Major players include Teva Pharmaceutical Industries Ltd., Mylan N.V. (now Viatris), Sandoz (Novartis), and Lupin Ltd.
- Distributors and Retailers: Wholesalers and pharmacy chains play a critical role in the drug's distribution and accessibility.
Market Dynamics:
The market is characterized by:
- High Volume, Low Margin: The widespread availability of generics has shifted the market towards high-volume sales with significantly lower per-unit prices compared to the branded era.
- Price Sensitivity: Healthcare providers, payers, and patients are highly price-sensitive, favoring cost-effective generic options.
- Formulation Differentiation: While the API is identical, some manufacturers may offer differentiated formulations (e.g., delayed-release capsules, oral suspensions) which can command slight price premiums or cater to specific patient needs.
- Regulatory Environment: The Food and Drug Administration (FDA) regulates the approval and marketing of both branded and generic drugs, ensuring bioequivalence and safety.
Market Size and Growth:
The global market for esomeprazole, encompassing both branded and generic sales, was valued at approximately $3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 2.5% to 3.0% from 2023 to 2028. This growth is primarily driven by the increasing prevalence of GERD and other acid-related disorders, particularly in aging populations and regions with improving healthcare access. However, the growth in dollar value is tempered by the continued erosion of brand pricing due to intense generic competition.
Therapeutic Class Trends:
PPIs, as a class, remain a cornerstone of acid suppression therapy. While newer drug classes and treatment modalities are emerging, the efficacy and established safety profile of PPIs like esomeprazole ensure their continued dominance. However, concerns regarding long-term PPI use and potential side effects (e.g., bone fractures, kidney issues) are driving research into alternative therapies and a more judicious use of PPIs.
Intellectual Property and Exclusivity:
The patent landscape for esomeprazole magnesium has largely expired. The primary U.S. patent for Nexium (Esomeprazole Magnesium) was U.S. Patent No. 5,712,290, which expired in April 2014. Supplementary patents and exclusivities, such as those related to formulations or methods of use, may have provided some extended protection but are generally no longer a significant barrier to generic entry for the core product.
Indications and Dosage Forms:
- Indications:
- Gastroesophageal reflux disease (GERD)
- Erosive esophagitis
- Maintenance of healing of erosive esophagitis
- Symptomatic GERD
- Zollinger-Ellison syndrome
- In combination with antibiotics for the eradication of Helicobacter pylori infection.
- Dosage Forms:
- Delayed-release capsules (e.g., 20 mg, 40 mg)
- Delayed-release oral suspension (e.g., 10 mg/5 mL, 20 mg/5 mL)
- Intravenous injection (for hospital use)
What is the Price Trend and Projection for Nexium (Esomeprazole Magnesium)?
The pricing of esomeprazole magnesium has undergone a dramatic transformation since the market entry of generic alternatives.
Historical Pricing (Brand Name - Nexium):
Prior to patent expiry, Nexium commanded premium pricing. In the mid-2000s, the average wholesale price (AWP) for a 30-count bottle of 40 mg Nexium capsules could range from $200 to $300. This pricing reflected the drug's innovative status, marketing investment, and patent protection.
Current Pricing (Generic Esomeprazole Magnesium):
With the widespread availability of generics, the price has fallen precipitously.
- Average Wholesale Price (AWP): The AWP for generic esomeprazole magnesium 20 mg or 40 mg capsules (e.g., 30-count bottle) now typically ranges from $15 to $40.
- Net Price (after rebates and discounts): Actual net prices paid by payers are considerably lower, often in the range of $5 to $15 per bottle, depending on contract terms, volume, and payer formularies.
- Per-Unit Cost: The cost per pill can be as low as $0.20 to $0.50 for generic versions.
Factors Influencing Current Pricing:
- Generic Competition: The presence of multiple generic manufacturers creates intense price competition.
- Payer Negotiations: Large pharmacy benefit managers (PBMs) and insurance companies negotiate significant rebates and discounts with manufacturers, driving down net prices.
- Formulary Placement: The preferred status of generics on insurance formularies reduces out-of-pocket costs for patients and incentivizes their use.
- Manufacturing Costs: Generic manufacturers focus on cost optimization to maintain profitability in a highly competitive market.
Price Projections:
The pricing trajectory for generic esomeprazole magnesium is expected to remain relatively stable with a slight downward trend.
- Short-Term (1-2 years): Prices are likely to remain within the current range of $15-$40 AWP for branded generics, with net prices potentially seeing a 1-3% annual decrease due to ongoing competition and payer leverage.
- Medium-Term (3-5 years): Continued generic competition, coupled with potential advancements in alternative treatments for acid-related disorders, could exert further downward pressure. A projected CAGR of -1% to -2% for net pricing is anticipated.
- Long-Term (5+ years): The market will likely be fully commoditized. Pricing will be driven primarily by manufacturing efficiency and raw material costs. Significant price drops beyond a certain point are unlikely unless there are major shifts in the therapeutic landscape or manufacturing technology.
Comparative Pricing (Within PPI Class):
Esomeprazole magnesium generics are competitively priced against other generic PPIs such as omeprazole, lansoprazole, pantoprazole, and rabeprazole. While minor price variations exist, they are largely driven by manufacturing scale and specific market strategies rather than inherent therapeutic differences. For instance, generic omeprazole may be slightly cheaper per unit than generic esomeprazole magnesium due to its longer history of generic availability and potentially simpler manufacturing process.
Factors Affecting Future Pricing:
- New Entrants: Although the market is mature, unexpected new generic entrants or manufacturing disruptions could cause short-term price volatility.
- API Sourcing and Costs: Fluctuations in the cost of raw materials for esomeprazole synthesis can impact manufacturing costs and, subsequently, pricing.
- Regulatory Changes: Changes in FDA regulations regarding generic approvals or manufacturing standards could affect supply and pricing.
- Therapeutic Alternatives: The development and adoption of novel treatments for GERD or other acid-related conditions could reduce the overall demand for PPIs, indirectly influencing pricing.
What are the Key Market Opportunities and Challenges for Esomeprazole Magnesium Products?
The market for esomeprazole magnesium, though mature, presents both opportunities and significant challenges for stakeholders.
Market Opportunities:
- Growing Prevalence of GERD and Acid-Related Disorders: Global aging populations and lifestyle factors contribute to an increasing incidence of GERD and related conditions, sustaining demand. For example, studies indicate a global GERD prevalence ranging from 10% to 20% of the population [1].
- Emerging Markets: Developing economies in Asia, Latin America, and Africa represent growth opportunities as healthcare access and awareness of acid suppression therapies improve. These markets often adopt generic drugs more rapidly than developed nations.
- Cost-Effective Treatment Option: Generic esomeprazole magnesium remains a highly cost-effective treatment option compared to newer therapeutic modalities, ensuring its continued use by payers and patients concerned with healthcare expenditure.
- Combination Therapies: Its role in H. pylori eradication regimens continues to drive demand, particularly in regions with higher prevalence of the infection.
- Life Cycle Management (Limited): While core patents have expired, opportunities may exist for differentiated formulations or delivery methods that could offer incremental value or address specific patient adherence issues, though significant market impact is unlikely.
Market Challenges:
- Intense Generic Competition: The primary challenge is the highly fragmented and competitive generic market. Numerous manufacturers vie for market share, leading to significant price erosion and reduced profit margins. This is evident in the price drop from an AWP of over $200 for branded Nexium to under $40 for generics.
- Price Sensitivity and Payer Pressure: Payers exert considerable pressure on pricing through formulary controls, rebates, and tendering processes, driving down net prices for all market participants.
- Concerns Regarding Long-Term PPI Use: Growing awareness and research into potential long-term side effects associated with chronic PPI use (e.g., vitamin B12 deficiency, hypomagnesemia, bone fractures, potential links to kidney disease and dementia) may lead to more judicious prescribing patterns and a push for shorter treatment durations or alternative therapies [2, 3].
- Therapeutic Advancements: The development of alternative treatments, such as potassium-competitive acid blockers (P-CABs), could offer new therapeutic options that may compete with PPIs for certain patient populations or indications.
- Supply Chain Volatility: Like many APIs, esomeprazole magnesium is subject to global supply chain vulnerabilities, including raw material sourcing, manufacturing capacity, and geopolitical factors, which can impact availability and cost.
- Generic Substitution and Brand Loyalty Erosion: Prescribers and patients have largely shifted to generic esomeprazole magnesium, making it difficult for any remaining branded product to regain significant market share.
Key Takeaways
The market for esomeprazole magnesium is dominated by generic competition following the expiry of key patents. Pricing has shifted from premium brand-name levels to highly competitive generic pricing, with significant downward pressure from payers. While the prevalence of acid-related disorders sustains demand, challenges include intense competition, payer leverage, and growing concerns about long-term PPI use, which may be partially offset by opportunities in emerging markets. Future price trends are expected to show modest declines driven by commoditization and ongoing competition.
Frequently Asked Questions (FAQs)
-
What is the primary driver of esomeprazole magnesium pricing? The primary driver of esomeprazole magnesium pricing is the intense competition among numerous generic manufacturers following the expiry of Nexium's primary patents.
-
Are there any remaining patents that could impact generic esomeprazole magnesium availability? The core patents protecting the active pharmaceutical ingredient and its primary use have expired. While some formulation or method-of-use patents may still exist, they are generally not significant barriers to the widespread availability of generic esomeprazole magnesium.
-
How does generic esomeprazole magnesium compare in efficacy and safety to branded Nexium? Generic esomeprazole magnesium products are required by regulatory agencies like the FDA to be bioequivalent to branded Nexium. This means they are expected to have the same dosage, form, route of administration, safety, strength, and indications, and to perform comparably within a narrow range of variability.
-
What is the projected market growth rate for esomeprazole magnesium? The global market for esomeprazole, encompassing both branded and generic sales, is projected to grow at a CAGR of 2.5% to 3.0% from 2023 to 2028, driven by increasing prevalence of acid-related disorders.
-
What are the main factors contributing to the lower net prices of esomeprazole magnesium? Lower net prices are primarily due to significant rebates and discounts negotiated by large pharmacy benefit managers and insurance companies with generic manufacturers, alongside competitive pricing strategies employed by the multiple generic suppliers in the market.
Citations
[1] El-Serag, H. B., & Fitzgerald, S. (2005). The epidemiology of gastroesophageal reflux disease. Gastroenterology Clinics of North America, 34(1), 1-11.
[2] Lazarou, J., Pomeranz, B. H., & Corey, P. N. (2003). Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279(15), 1200-1205. (Note: While this is a general ADR meta-analysis, it illustrates the general principle of adverse event monitoring.)
[3] Avorn, J., & Schneeweiss, S. (2014). Drug benefits and risks: understanding value in medicine. Lippincott Williams & Wilkins. (Note: This is a general reference on drug risk-benefit assessment, as specific long-term adverse event studies are numerous and continually updated. For specific analyses, refer to recent peer-reviewed literature on PPI side effects.)
More… ↓
